AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06690411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept
Description: The participants of the Mulligan SNAG group will undergo the Mulligan SNAG technique. Mulligan's SNAG technique is a gentle manual therapy method. This technique is based on the correction of the joint position. There are 3 techniques specified for headache; Headache SNAG, Reverse Headache SNAG, and C1-C2 SNAG.
Study NCT06690411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: Myofascial therapy can be described as massage-type manual therapy. The participants of the Myofascial Release Group will undergo the myofascial release technique.
Study NCT06415903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3117 tablets
Description: TQB3117 is a protein inhibitor.
Study NCT05113953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Sustained-release oral tablets
Study NCT05113953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study NCT05113953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT05790772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous Exercise
Description: 50 minutes of running on a treadmill
Study NCT06262269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity program supervised by an APA teacher via individual video conference.
Description: Participants will follow a 12-week tele-rehabilitation programme involving high-intensity interval training (HIIT) adapted to their AIS. The programme includes three 45-minute individual sessions per week. The exercises are selected from a database designed for AIS patients. The APA teacher will systematically document the patient's presence or absence at each tele-rehabilitation session, thus assessing their adherence to the programme.
Study NCT06262269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First period of the home-based adapted physical activity program with an exercise booklet.
Description: Participants will receive a self-programme in the form of a booklet of specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
Study NCT06262269 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second period of the home-based adapted physical activity program with an exercise booklet.
Description: Participants will receive a self-programme in the form of a booklet containing specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
Study NCT06262269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second period of the home-based adapted physical activity program with an exercise booklet.
Description: Participants will receive a self-programme in the form of a booklet containing specific HIIT-type exercises adapted to their AIS. The programme is to be carried out at home over a 12-week period, with 3 45-minute sessions per week. The exercises are taken from the same database. Each participant in the CONTROL group will be encouraged to keep a follow-up diary, noting the date, start time and end time of each session (in order to assess adherence to the sessions).
Study NCT04708028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dog Therapy
Description: The intervention is a therapy dog interaction (e.g. petting) for up to 2 minutes before their appointment and first interaction with the doctor. The subject can pet the dog for as long as they like up until the 2 minute mark.
Study NCT05536141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Administered as specified in the treatment arm
Study NCT05128617 — intervention group
Intervention type: DRUG
Intervention: Epirubicin-cyclophosphamide
Description: 1 cycle of Epirubicin-cyclophosphamide
Study NCT05128617 — intervention group
Intervention type: DRUG
Intervention: Paclitaxel
Description: 1 cycle of Paclitaxel
Study NCT05652257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-brensocatib
Description: Oral solution.
Study NCT06627218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
Study NCT06628128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNT-517 Tablet
Description: JNT-517: 75 mg BID
Study NCT04723537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Upamostat 200 mg
Description: 1 capsule comprising 200 mg of upamostat and 1 capsule comprising matching placebo.
Study NCT04723537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Upamostat 400 mg
Description: 2 capsules, each capsule comprising 200 mg of upamostat
Study NCT04723537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A and B: Placebo
Description: 1 or 2 capsules, each capsule a matching placebo
Study NCT04723537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Upamostat 200 or 400 mg
Description: Based on dose selection from Part A, Part B Upamostat will be EITHER a single 200 mg dose of upamostat OR two 200 mg doses of upamostat, for a total of 14 days.
Study NCT05606705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Baked Milk
Description: Participants to regularly eat a baked milk muffin for 6 weeks
Study NCT05899725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence
Study NCT05899725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids and Ruxolitinib
Description: Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
Study NCT05771571 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional olive oil, enhanced with orange peel extract
Description: The functional olive oil was enriched with 10% w/w orange peel extract
Study NCT05771571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Refined olive oil
Study NCT06649604 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Anesthesia Device
Description: The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device
Study NCT06649604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Description: Laser treatment for diabetic retinopathy done in a standard fashion
Study NCT06649604 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation
Description: Laser treatment for diabetic retinopathy done in a standard fashion
Study NCT06144606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecartus
Description: Tecartus is a CD19 directed CAR T-cell therapy that utilizes CD28 costimulatory and CD3 zeta stimulatory domains. Tecartus is manufactured from purified autologous T-cells via retroviral transduction with a median time to product release of 13 days.
Study NCT06422884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENV-101
Description: oral tablet, dosed once a day
Study NCT06422884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, dosed once a day
Study NCT05619510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRIME Intervention
Description: Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
Study NCT05619510 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PRIME Intervention
Description: Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.
Study NCT06487559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous infusion
Study NCT06487559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous infusion
Study NCT06346795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-filling flowable dental composite
Description: Class II restorations will be performed with G-aenial Universal Injectable, Grandio Flow, and Clearfil Majesty Flow high-filling flowable composites.
Study NCT05953038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Tartrate
Description: D-Lysergic Acid Diethylamide (LSD) D-tartrate as oral drinking solution (water / ethanol 20% m/m)
Study NCT05035654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-220 Design 1 (Part 1 only)
Description: LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1
Study NCT05795855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADEPT
Description: Prenatal providers will participate in trainings that will lay the foundation for an effective vaccination recommendation. After the completion of training, prenatal care providers will begin making recommendations promoting the importance of maternal and childhood vaccinations to pregnant individuals, as part of routine prenatal care. The core component of ADEPT is prenatal provider training to enable a vaccination recommendation, encouraging pregnant individuals to receive vaccines during pregnancy and for their child after birth. Pregnant individuals who remain vaccine hesitant despite the provider recommendation, will be eligible to receive the adaptive components of ADEPT in the form of evidence-based educational materials on vaccinations and phone consultations with a vaccine navigator to discuss residual concerns.
Study NCT06521463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN FLX Pro LAAC Device
Description: WATCHMAN FLX Pro LAAC Device Implantation
Study NCT06521463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WATCHMAN FLX Pro LAAC Device
Description: WATCHMAN FLX Pro LAAC Device Implantation
Study NCT04943211 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fluorodeoxyglucose (18F-FDG)
Description: max 6 MGBq/kg, no more than 100
Study NCT05779852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-hypnosis and dressing
Description: self-hypnosis during dressing
Study NCT05779852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dressing
Description: dressing without self-hypnosis
Study NCT06270992 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NCCN (National Comprehensive Cancer Network) diagnosis
Description: For diagnostic evaluation, the necessary procedures from the standard protocols consisting of anamnesis, physical examination, laboratory tests, radiological imaging methods, and tissue biopsy will be followed. Computerized Tomography (CT) and Positron Emission Tomography-Computed Tomography (PET-CT) will be used as imaging methods, while fiberoptic bronchoscopy and video-assisted mediastinoscopy will be applied for tissue diagnosis and staging.
Study NCT05035654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYR-220 Design 2 (Part 1 and Part 2)
Description: LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive TIPC
Study NCT06279013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive handbook
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Receive IVR symptom monitoring
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring
Description: Receive IVR symptom monitoring
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06279013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06217146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Cannabis
Description: MediCane's medical cannabis oil
Study NCT06217146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Placebo Oil
Study NCT05035654 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bilateral sham procedure control (Part 2)
Description: Bilateral sham procedure control
Study NCT04811079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 419 nm Spectacle Filter
Description: TEST
Study NCT06717269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948 capsule
Description: NX-5948 in capsule form
Study NCT06717269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-5948 tablet
Description: NX-5948 in tablet form
Study NCT06717269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsule, once daily
Study NCT06731023 — intervention group
Intervention type: DRUG
Intervention: Bismuth
Description: Bismuth 0.6g bid
Study NCT05914779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No use of antibiotics
Description: Subjects will be randomized into antibiotics and no antibiotics groups based on inclusion and exclusion criteria
Study NCT06731023 — intervention group
Intervention type: DRUG
Intervention: Vonoprazan
Description: vonoprazan 20mg bid
Study NCT06731023 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin 1g bid
Study NCT06731023 — intervention group
Intervention type: DRUG
Intervention: Rifabutin
Description: Rifabutin 0.15g bid
Study NCT06731023 — intervention group
Intervention type: DRUG
Intervention: Metronidazole
Description: Metronidazole 400mg qid
Study NCT06731023 — intervention group
Intervention type: DRUG
Intervention: Other antibiotics
Description: The selection of other antibiotics is based on the results of drug susceptibility testing.
Study NCT06737367 — intervention group
Intervention type: OTHER
Intervention: CT radiomic analysis
Description: Radiomic features of tumor and peritumor tissue
Study NCT06742606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group 1 of patients will receive Adalimumab while Group 1 will receive ustekinumab
Description: All the patients will be treated according to guidelines of ECCO/ESPGHAN and will be followed up regularly for 12 months by assessment~• response to treatment Frequency of relapses,~Regular assessment will be:~Clinically every 2 to 4 weeks at gastroenterology outpatient clinic by using activity scoring systems:~pediatric Ulcerative Colitis Activity Index pediatric Chron's Disease Activity Index~Laboratory follow up will done at weeks 12,24,36,48 of starting or changing to other biological by doing inflammatory markers( CBC, ESR, CRP, albumin. At the end of study(week 48) each patient will be reassessed by:~Disease activity:~Laboratory Endoscopy will be repeated at week 48 of starting or changing to other biological to assess effect of biologicals on reach mucosal healing.
Study NCT06743451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health workers training on GMP guideline
Description: One day training will be conducted to health workers on updated GMP guideline for the health workers primarily engaged in Growth monitoring and promotion of the children.
Study NCT06743451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female community health volunteers' mobilization for inviting mothers and caretakers
Description: Female community health volunteers will be mobilized for inviting mothers and caretakers for two consecutive months for enhancing GMP practices in the municipality
Study NCT06743438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Amibufenamide（TMF）
Description: Once-daily oral dose of 25 mg TMF were maintained in all participants
Study NCT06741956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weapom Lifestyle Intervention to measure bone impacts using a Fitbit Versa wearable device and the Weapom App.
Description: A. Program to increase physical activity and impacts For the intervention, a biosensor -wearable device- (Fitbit Versa) will be used. The device is linked to an App (Weapom) that will allow users to quantify the number of steps (including the rate of steps per minute), the impacts and their intensity. Users will be given feedback from the application on the level of achievement of the objectives proposed in the impact program (EV). It will be proposed to achieve 50 vertical and multidirectional jumps per day (milestone 1. The number of jumps> 3.9 G per day will be recorded 28, divided between 3-5 sets of 10-20 repetitions with a minimum 1-2 minute rest between sets. A frequency between 4-7 days per week will be used. In the same way, it will be recommended to reach 10,000 steps per day (milestone 2. The number of daily steps will be recorded) and, as far as possible, at a rapid pace (milestone 3. The number of daily minutes walking at a pace over 110 steps/minute will be r
Study NCT06741488 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Exercise Adaptation Rating Scale
Study NCT06743321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-to-speech Voice-Cloning Care (SVCC)
Description: After patients in the intervention group were transferred to the ICU, the SVCC intervention was initiated. It is administered three times daily: in the morning, at noon, and in the evening. The SVCC intervention includes three types of activities: awakening, reassurance, and preparatory exercises for the removal of the endotracheal tube (ETT). Before each intervention is carried out, the clinical status of the participants must be assessed to determine whether they are suitable for SVCC and to decide on the specific content of the intervention. Once the removal of the ETT is implemented, the SVCC intervention will no longer be carried out.
Study NCT03984565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: High-CBD, low-THC sublingual product formulated in palm oil
Study NCT05914779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: with antibiotics treatment
Description: with antibiotics treatment
Study NCT06481358 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Artificial intelligence
Description: AI extract intestinal region and reconstruct into 3D image.
Study NCT05545397 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
Study NCT05545397 — intervention group
Intervention type: DEVICE
Intervention: EEG montior
Description: And pump propofol at a rate of 600ml/h. The degree of sedation was assessed by the MOAA/S scale until the depth sadation of the patient during the monitor of EEG
Study NCT04811079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 437 nm Spectacle Filter
Description: TEST
Study NCT03984565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual product formulated in palm oil with supplemental terpenes to match CBD product.
Study NCT04811079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 456 nm Spectacle Filter
Description: TEST
Study NCT04811079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 476 nm Spectacle Filter
Description: TEST
Study NCT04811079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 373 nm Spectacle Filter
Description: CONTROL
Study NCT04718090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: Pericapsular nerve group block in shoulder surgery.
Study NCT06067477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D Supplement
Description: Vitamin D Supplement
Study NCT05738980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous RAK cells
Description: Autologous RAK cells were treated by intravenous reinfusion